Becton Dickinson & Co. (BDX) — AI Analysis & Mentions

Despite recent share price weakness, discounted cash flow analysis suggests a 27.5% undervaluation, with intrinsic value at $214.69 versus the current $155.65. Its P/E ratio is also lower than the industry’s fair value, hinting at a potential bargain for patient, value-oriented investors.

BDX is highlighted as a 'quiet giant' of healthcare. While not flashy, its steady business, essential products, and consistent growth fit the mold of a classic defensive holding—illustrating Buffet's love for dull-but-dependable businesses with enduring demand.